Multiple analysts initiated Buy ratings on Lineage, citing its strong acquisition track record and technological investments. Analysts project high single-digit growth in AFFO and EBITDA for Lineage ...

Ratings for Lineage Cell Therapeutics (AMEX:LCTX) were provided by 7 analysts in the past three months, showcasing a mix of bullish and bearish perspectives. The table below provides a snapshot of ...

CNBC is now accepting nominations for the 2026 Disruptor 50 list. Submit a nomination before February 23. Lineage closed up more than 3% during its market debut Thursday on the Nasdaq after going ...